Novo Nordisk Pulls Unlucky NovoSeven Application In EU

 
• By Kathleen Michael

Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.

More from Archive

More from Pink Sheet